Halozyme Therapeutics (HALO) Other Operating Expenses (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Other Operating Expenses data on file, last reported at $108.8 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $108.8 million, up 64.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $681.6 million (up 172.06% YoY), and the FY2025 annual result was $639.0 million, up 177.27% from the prior year.
• Other Operating Expenses declined to $108.8 million in Q1 2026 per HALO's latest filing, from $435.7 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $435.7 million in Q4 2025 and troughed at $15.9 million in Q1 2022.
• A 5-year average of $83.9 million and a median of $66.2 million in 2025 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Operating Expenses fell 15.52% in 2024, then soared 628.44% in 2025.
• A 5-year view of Other Operating Expenses shows it stood at $46.7 million in 2022, then soared by 50.11% to $70.1 million in 2023, then retreated by 14.62% to $59.8 million in 2024, then soared by 628.44% to $435.7 million in 2025, then slumped by 75.04% to $108.8 million in 2026.
• Business Quant data shows HALO's Other Operating Expenses at $108.8 million in Q1 2026, $435.7 million in Q4 2025, and $73.0 million in Q3 2025.